Filing Flows › BridgeBio Pharma (BBIO) › Q2 2026 › vs Q2 2025
BridgeBio Pharma (BBIO) Q2 2026 vs Q2 2025 (year over year)
BridgeBio Pharma's revenue rose $133M (+120%) from $111M in Q2 2025 to $244M in Q2 2026. The biggest changes: Net product revenue +$151M (+211%); License and services revenue −$31.6M (-84%); Royalty revenue +$13.8M (+850%).
BridgeBio Pharma, Q2 2026: revenue $244M (+120% year over year), operating margin -43.9%, net loss $156M, operating cash flow −$71.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Net product revenue | $222M | $71.5M | $151M | +211% |
| Royalty revenue | $15.4M | $1.6M | $13.8M | +850% |
| License and services revenue | $5.8M | $37.4M | −$31.6M | -84% |
| Revenue | $244M | $111M | $133M | +120% |
| Net loss | $156M | $184M | −$27.9M | -15% |
| Costs & expenses | $400M | $294M | $105M | +36% |
| Operating costs | $351M | $245M | $106M | +43% |
| Interest & other, net | $48.8M | $47.4M | $1.4M | +3% |
| Cost of revenue | $15.0M | $3.7M | $11.4M | +312% |
| Research & development | $149M | $111M | $38.2M | +34% |
| SG&A | $186M | $129M | $57.1M | +44% |
| Operating cash sources | $156M | $184M | −$27.9M | -15% |
| Depreciation & amortization | $1.1M | $1.3M | −$264K | -20% |
| Share-based compensation | $44.1M | $37.2M | $6.8M | +18% |
| Working capital & other | $39.7M | $64.5M | −$24.9M | -39% |
| Cash used in operations | $71.1M | $80.7M | −$9.6M | -12% |
| Net loss absorbed | $156M | $184M | −$27.9M | -15% |
Questions
How much did BridgeBio Pharma's revenue grow year over year in Q2 2026?
BridgeBio Pharma's revenue rose $133M (+120%) from $111M in Q2 2025 to $244M in Q2 2026.
What drove BridgeBio Pharma's revenue change in Q2 2026?
Net product revenue +$151M (+211%); License and services revenue −$31.6M (-84%); Royalty revenue +$13.8M (+850%).